OBJECTIVES: Very few studies have tried to evaluate comparative patient ratings of physician satisfaction across specialties. We examined the differences in physician satisfaction reported by patients accessing care from pediatricians versus other primary care physicians. METHODS: We conducted a cross sectional, national web based survey study consisting of anonymous patients who rated their physicians on the basis of treatment satisfaction that they received from their most recent outpatient visits. The survey was user friendly, validated and helped patients identify their physicians as per specialties and rate them on a scale of 0 ("not at all satisfied") to 10 ("extremely satisfied"). The association of physician satisfaction between pediatricians and nonpediatricians was assessed using hierarchical linear model (HLM). RESULTS: Using 6982 patient survey responses, we matched 2724 PCP visits with a similar number of visits to pediatricians. After controlling other variables, pediatricians were associated with higher satisfaction, on average, than other PCPs (r03 = 14.79, p < 0.000). Spending time with patients was positively associated with patient satisfaction (r50 = 3.49, p < 0.000) holding all other factors in the model constant. However, pediatricians were associated with lower time spent with patients (r53 = −1.1, p = 0.045). After controlling for other variables, waiting time was negatively associated with patient satisfaction (r40 = −0.37, p = 0.000). CONCLUSIONS: Our study finds that pediatricians are associated with higher patient satisfaction score than non-pediatricians. Increased time spent with the patient by pediatricians convinced to other PCPs to be the driver of the effect.
PMC33 THE TRANSLATION AND LINGUISTIC VALIDATION OF THE EQ-5D ELECTRONIC VERSION (EQ-5D EPRO)
Ashcroft-Jones AJ 1 , Furtado T 1 , Wild D 2 1 Oxford Outcomes, Oxford, Oxon, UK, 2 Oxford Outcomes Ltd, Oxford, Oxon, UK OBJECTIVES: The objective of this study was to produce translations of the ePRO version of the EQ-5D that are conceptually equivalent to the original and other language versions, ensuring that the resulting translations are suitable for use in the ePRO format. METHODS: The methodology employed was: 1 forward and 1 back translation, review, developer review, linguistic validation interviews with 5 respondents (a mix of lay people and patients), second developer review and 2 proofreadings. RESULTS: The translation process highlighted numerous issues: 1) 'Tap', meaning to press lightly on the screen with a stylus, proved problematic in translation. In some languages, a literal translation would result in the patient touching the screen too lightly, not understanding that pressure was required. In other languages, there was no exact translation available. 'press' or 'touch with the stylus' were used as alternatives (French and Russian respectively), ensuring that patients could navigate the platform; 2) In some Romance languages, the emphasis of 'tap ONE box', meaning only one, became lost due to the languages' requirement of an article. Some translators used a capitalised definite article ('THE'), others placed 'ONLY ONE' in brackets to provide the stress; 3) The Eastern European translators maintained that there is isno literal translation of 'heading', in the context of a title with sentences underneath. To render the intended meaning, they used 'the text in bold' or 'in each of the groups'; 4) Some languages found 'Please do this by [. . .]' a difficult construction to translate directly and colloquially. The expression was substituted with 'You do it by [. . .]', which was more idiomatic. CONCLUSIONS: The EQ-5D ePRO has been translated and linguistically validated using a rigorous translation process. A number of cultural and linguistic issues became apparent and were resolved. The measure is now appropriate for use in multinational trials.
PMC34 SUPPLEMENTAL METHODOLOGY FOR TRANSLATING INSTRUMENTS DEVELOPED IN A LANGUAGE OTHER THAN ENGLISH
Handa M 1 , Gawlicki M 2 , McKown S 1 , Lauritzen M 1 , Hasegawa N 1 1 Corporate Translations, Inc, Chicago, IL, USA, 2 Corporate Translations, Inc, East Hartford, CT, USA OBJECTIVES: Procedures used to linguistically validate PROs are well documented for instruments originally developed in English. However, methodology concerning non-English based measures is largely uncharted. This paper outlines the challenges associated with translating PROs developed in a language other than English and recommends supplemental methodology for improving this process. METHODS: To establish guidelines for translating non-English PROs, several case studies of previous validations were performed. Techniques used to validate the Cancer Dyspnoea Scale (Japanese) were compared to those used for the Pain Detect Scale (German), DN4 Questionnaire (French), and the Hôtel Dieu 16 (French). All questionnaires were translated from their source language into US English. The DN4 was subsequently translated into Dutch, while the CDS was translated into seven additional languages. Special attention was paid to maintaining conceptual equivalence, addressing colloquialisms native to the development setting and compensating for differing grammatical rules. RESULTS: Linguistically validating non-English PROs poses numerous problems. Since most translators and project managers are English-based, an English adaptation of the instrument may need to be created prior to moving forward with other translations. Extreme care must be taken to accurately interpret all of the source instrument's concepts. Recommended enhancements to the standard validation process include: assigning a project manager skilled in the source language to oversee all subsequent translations; creating a concept elaboration guide for both the original instrument and the English translation; conducting a specialized training session with translators to review the development of the original document and the English translation; placing extra emphasis on the meaning of colloquialisms and the formulation of response sets. CONCLUSIONS: Linguistically validating PRO questionnaires developed in non-English settings presents special challenges. Evidence suggests that, in these situations, standard procedures may be insufficient to produce conceptually equivalent translations acceptable for use in multinational clinical trials. In such cases, expanded procedures are recommended.
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ISSUES IN THE TRANSLATION AND LINGUISTIC VALIDATION OF EPRO AND IVRS INSTRUMENTS
Gordon-Stables R, Wild D Oxford Outcomes Ltd, Oxford, Oxon, UK OBJECTIVES: ePRO and IVRS PRO instruments are increasingly used in clinical trials. As a result translations of such instruments are also increasingly required. Whilst the approach recommended in the ISPOR translation task force paper (Wild et al. 2005) should still be used, ePRO and IVRS instruments present some unique challenges during their translation and linguistic validation. This study seeks to clarify what some of those challenges are, and how to meet them. METHODOLOGY: Oxford Outcomes translation and linguistic validation projects involving ePRO/IVRS were reviewed to produce a list of tips on how best to localise such instruments. RESULTS: Give translators information about limited screen size up front to avoid shortening strings later in the process. Participants in IVRS studies have to listen to the PRO instrument; therefore prompts should not be too long and have too many concepts (this helps both translators and participants). Avoid concatenation (where a sentence is split in the software coding and put back together at run time). Don't split question stems from the questions. Provide translators with existing translations leveraged from previous translation projects to ensure consistency. Ideally cognitive debriefing of the translation should be carried out via the medium of final delivery (e.g. if it is on a handheld computer, the participants see the instrument on a handheld computer). It is worth having a linguist check final translated software/listen to recorded prompts-to ensure no errors have been introduced at software building / recording stage. CONCLUSIONS: With some forward planning, the challenges of translating and validating an ePRO or IVRS instrument can be met, ensuring a translation that is conceptually equivalent and suitable for use in the target country with the target patient population.
PMC36
VALIDITY OF SELF-REPORT WITH RESPECT TO PRESCRIPTION MEDICATIONS AMONG PREGNANT WOMEN
Jaiswal P, Sarangarm P, Young B, Khan N, Dodd M, Phelan S, Rayburn W, Bakhireva L University of New Mexico Health Sciences Center, Albuquerque, NM, USA OBJECTIVES: Accuracy of self-report regarding prescription medication use among pregnant women is largely unknown. Accurate self-reported information is needed for medication reconciliation purposes, clinical management, clinical teratology research, and monitoring of adherence. This study examines the accuracy of self-reported medication use by pregnant women for medications used chronically and episodically or intermittently during pregnancy. METHODS: This was a cross-sectional analysis of data collected through the University of New Mexico (UNM) cohort study, "Safety of Medication and Perception of Teratogenicity" (SMART). Pregnant women were recruited from UNM prenatal care clinics and were asked to report all medications they took since their last menstrual period. The analysis was limited to women enrolled in the first year of the study who had at least one prescription for diabetes or opioid analgesics medications (representative of chronic and acute medication use, respectively). The accuracy of agreement between self-report and medical records for each medication class was estimated by simple (κ) and prevalence and bias adjusted (PABAK) kappa. Information from the medical records was used as the 'gold-standard'. RESULTS: A total of 92 pregnant women were included in the analysis. Agreement for diabetes medications was near perfect (κ = 0.87; PABAK = 0.91); whereas poor-to-moderate concordance was observed for opioid analgesics (κ = 0.29; PABAK = 0.57). Among antidiabetic medications, concordance was highest for biguanides (κ = 0.90; PABAK = 0.93) and lowest for sulfonylureas (κ = 0.83; PABAK = 0.87); whereas among opioid analgesics, highest agreement was observed for strong agonists (κ = 0.51; PABAK = 0.56) and lowest for moderate/low agonists (κ = 0.06; PABAK = 0.59). CONCLUSIONS: This study suggests poor accuracy of self-report with respect to prescription medications used as short courses or intermittently during pregnancy. Therefore, in clinical studies assessing safety of such medications in pregnancy, self-reported information needs to be supplemented by other sources. Accuracy of self-report for medications used chronically is acceptable. 
PMC37 PATIENT REPORTED OUTCOME RECALL PERIODS IN LIGHT OF THE FINAL FDA GUIDANCE
